Observational studyJournal of Korean medical science2026
Sex Differences in Treatment Response to Targeted Therapy in Rheumatoid Arthritis: A Post Hoc Analysis of a Prospective Observational Study.
Observational study in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex differences in rheumatoid arthritis: results of a cross-sectional study.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSex differences in treatment outcomes for rheumatoid arthritis (RA) have been inconsistently reported. This study aimed to investigate whether male and female patients with RA have different treatment responses to their first-line targeted therapies.
methodsThis post hoc analysis used data from a prospective multicenter observational study of patients with RA initiating biologic disease-modifying anti-rheumatic drugs or Janus kinase inhibitors for the first time. The primary outcome was remission measured by the 28-joint Disease Activity Score with erythrocyte sedimentation rate (DAS28-ESR) at week 24. Remission rates were compared between male and female patients. Conditional logistic regression models, matched on RA disease duration and baseline disease activity, were used to analyze the independent effect of sex on remission.
resultsOverall, 78 male and 428 female patients were included. In the per-protocol analysis, the DAS28-ESR remission rates at week 24 were higher in male patients (44.3%) than in female patients (28.9%) (
conclusionMale patients with RA achieve higher remission rates than female patients when initiating first-line targeted therapies, particularly in early disease. These findings suggest the need for sex-specific strategies in RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.